Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients – the Tuebingen experience

Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients – the Tuebingen experience

Purpose To evaluate the treatment of selected patients with uveal melanoma with endoresection and adjuvant ruthenium brachytherapy. Methods Thirty‐five patients with uveal melanoma not suitable for ruthenium plaque monotherapy were treated with endoresection and adjuvant ruthenium brachytherapy betw...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) Vol. 95; no. 8; pp. e727 - e733
Main Authors: Süsskind, Daniela, Dürr, Carina, Paulsen, Frank, Kaulich, Theodor, Bartz‐Schmidt, Karl U.
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-12-2017
Subjects:
Acuity
Brachytherapy
Complications
endoresection
Enucleation
Melanoma
Metastases
Metastasis
Monosomy
ocular oncology
Radiation
Radiation therapy
Retinopathy
Ruthenium
Survival
Tumors
uveal melanoma
Visual acuity
ocular oncology
endoresection
brachytherapy
uveal melanoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the treatment of selected patients with uveal melanoma with endoresection and adjuvant ruthenium brachytherapy. Methods Thirty‐five patients with uveal melanoma not suitable for ruthenium plaque monotherapy were treated with endoresection and adjuvant ruthenium brachytherapy between January 2001 and October 2013. Recurrence‐free survival, globe retention, course of visual acuity (VA), occurrence of therapy‐related complications and metastasis‐free and overall survival were analysed retrospectively. Results Eight patients (22.9%) had a tumour recurrence after a median follow‐up of 49.5 months (range: 21–134 months). Enucleation was necessary in eight patients. Thirty‐two patients (91%) had a loss of VA with a median loss of nine lines (range: 0 to −39 lines); VA was stable in three patients and no patients had a gain in VA. Four patients (11.4%) developed radiation retinopathy. Metastases were detected in seven patients (20.0%) during follow‐up. The occurrence of metastasis was significantly associated with monosomy 3 (p < 0.0001). Twenty‐four patients (68.6%) were alive at the end of follow‐up. Five patients (14.3%) died because of uveal melanoma (UM) metastasis. Conclusions Endoresection with adjuvant ruthenium brachytherapy is an option for selected patients with UM who cannot be treated with brachytherapy as monotherapy. About two‐thirds of eyes can be retained long term without recurrences. Visual acuity cannot be maintained in most cases, and may even decrease considerably. Radiation complications are comparatively rare and not a significant problem.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1755-375X
1755-3768
DOI:10.1111/aos.13306